Navidea Biopharma (NAVB) Moves Higher as Insiders Buy Back In
Article
Related Press Releases (1)
Related Articles (1)
Related SEC Filings (5)
Stock Quotes (1)
Comments (0)
Tweet
Send to a Friend
Get Alerts NAVB Hot Sheet
Down)
Trade NAVB Now!
Navidea Biopharmaceuticals (Nasdaq: NAVB) is higher on the session Friday amid a mix of insider buying recently.
Disclosing purchases made 12th are:
Notably, the pharma was issued a CRL from the FDA on September 10th for Lymphoseek. Shares are down over 20 percent for the week, but up about 6 percent today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Disclosing purchases made 12th are:
- Director Brendan Ford - on September 12th for 5,000 shares and total cost of $13,200;
- Director Gordon Troup bought 5,000 on August 15th and 5,000 on September 12th. The cost was $31,080;
- CEO Mark J. Pykett acquired 4,000 on September 11th. Gross cost of $10,552; and
- Business Chief Tom Tulip bought 15,000 shares at $2.70 for gross cost of $40,500 on September 14th.
Notably, the pharma was issued a CRL from the FDA on September 10th for Lymphoseek. Shares are down over 20 percent for the week, but up about 6 percent today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
- MoSys (MOSY) CEO Takes Down 250K Shares in Recent Offering
Create E-mail Alert Related Categories
Insider Trades, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
